Camrelizumab, Apatinib Plus Hepatic Arterial Infusion Chemotherapy Versus Camrelizumab and Apatinib for Hepatocellular Carcinoma with Portal Vein Invasion: a Randomized, Open-label, Multicentre Trial

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 29 Nov 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Camrelizumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin; Rivoceranib
Indications Liver cancer
Focus Therapeutic Use

27 Nov 2024 Status changed from recruiting to active, no longer recruiting.
04 Jun 2024 Study design presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
25 Jan 2022 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com